Chinese Expert Consensus Standardizes Delta-like Ligand 3-T Cell Engager (DLL3-TCE) Therapy for Small Cell Lung Cancer (SCLC)

Small cell lung cancer (SCLC) is highly aggressive, characterized by early metastasis and poor prognosis, posing a significant challenge in oncology. While immune checkpoint inhibitors (ICIs) have improved overall survival, substantial room for better clinical outcomes remains. Delta-like ligand 3-T cell engager (DLL3-TCE) therapy represents an emerging T cell-targeted immunotherapy, precisely directing T cells to attack tumor cells. This novel mechanism offers breakthrough potential, particularly with Tarlatamab already approved, but clinicians need clear guidance on its complex mechanisms and appropriate use.

The Small Cell Lung Cancer Expert Committee of the Chinese Society of Clinical Oncology convened a consensus panel to address the lack of in-depth understanding regarding DLL3-TCE therapies. This panel systematically developed the Chinese Expert Consensus on Delta-like Ligand 3-T Cell Engager Therapy for SCLC. The consensus was formulated based on a rigorous review of evidence-based medicine and extensive expert practical experience, aiming to provide comprehensive, standardized guidance for the clinical application of DLL3-TCE agents in China.

The expert consensus provides detailed guidance across several critical domains to standardize the clinical use of DLL3-TCE agents in SCLC. It elucidates the intricate mechanisms of action of these novel T cell engagers, explaining how they bridge T cells to DLL3-expressing tumor cells for targeted cytotoxicity. Furthermore, the consensus outlines criteria for identifying appropriate patient populations, ensuring optimal selection for DLL3-TCE therapy. This includes considerations for disease stage, prior treatments, and biomarker status to maximize therapeutic benefit.

The consensus specifically addresses comprehensive clinical management strategies, including best practices for dosing, administration, monitoring for adverse events, and managing potential toxicities associated with this class of immunotherapy. This guidance aims to bridge the knowledge gap for clinicians, ensuring safe and effective integration of agents like Tarlatamab into routine SCLC treatment protocols, thereby maximizing therapeutic benefit while minimizing risks and improving patient outcomes.